Abstract
The unintended presence of particulate matter in injectable products is an indicator of the quality of the product. Subvisible particulates have historically been monitored through methods such as light obscuration and membrane microscopy, as outlined in the United States Pharmacopeia (USP) General Chapter <788> or the equivalent Ph Eur 2.9.19 and the Japanese Pharmacopeia General Chapter 20. These methods were designed to protect patients against the risk of capillary occlusion though the infusion of “foreign” particulate matter. With the development and commercialization of protein therapeutics, the application of these methods has to be adapted to the special requirements posed by such products. Apart from the “foreign” particulates, therapeutic protein products may also contain particulates that are inherent to the product, arising as a consequence of protein self-association or aggregation. The nature of these inherent “proteinaceous” particulates is generally different than the traditional “foreign” particulates. Proteinaceous particulates tend to be of an amorphous irregular morphology, soft, with a refractive index resulting in low contrast against an aqueous background, making them more difficult to detect and count compared to the “foreign” particulates. The growing realization of the importance of monitoring all (foreign as well as inherent) particulates in therapeutic protein products has led to a number of developments in this area including techniques of measurement. Here, we summarize a number of the procedures used for subvisible particle measurements, with new techniques as well as refinements to existing techniques.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Carpenter JF, Randolph TW, Jiskoot W et al (2009) Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci 98(4):1202–1205
Singh SK, Afonina A, Awwad M et al (2010) An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 99(8):3302–3321
Narhi LO, Jiang Y, Cao S et al (2009) A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 10(4):373–381
US Pharmacopeia (2011) USP/NF General Chapter <788>. Particulate matter in injections. In: US Pharmacopeia, National Formulary, USP34/NF-29 (suppl. 1). Rockville, MD
European Pharmacopoeia (2011) 7th edn. (7.2). General Chapter 2.9.19. Particulate contamination: sub-visible particles. European Pharmacopoeia Commission, Council of Europe, European Department for the Quality of Medicines
Japanese Pharmacopoeia (2011) 16th edn. General Chapter 20. Foreign insoluble particulate matter test for injections. Society of Japanese Pharmacopoeia
Sharma DK, King D, Moore P et al (2007) Flow microscopy for particulate analysis in parenteral and pharmaceutical fluids. Eur J Parenter Pharm Sci 12(4):97–101
Filipe V, Hawe A, Jiskoot W (2010) Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 27(5):796–810
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Singh, S.K., Toler, M.R. (2012). Monitoring of Subvisible Particles in Therapeutic Proteins. In: Voynov, V., Caravella, J. (eds) Therapeutic Proteins. Methods in Molecular Biology, vol 899. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-921-1_24
Download citation
DOI: https://doi.org/10.1007/978-1-61779-921-1_24
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-920-4
Online ISBN: 978-1-61779-921-1
eBook Packages: Springer Protocols